TGFB1 and chronic kidney disease: These data align with the previous studies, where therapeutic targeting of TGF-β and WNT/β-catenin pathway ameliorated fibrosis in rodent models of CKD [63], and reduced fibroblast gene activation, potentially improving fibrosis [64].